Anthera Pharmaceuticals (United States)

Recent papers from Anthera Pharmaceuticals (United States)

1. Muscle function, linear growth, and bone health during 30 months of vamorolone, prednisone, and deflazacort treatment for Duchenne muscular dystrophy: a comparative studyJournal of Bone and Mineral Research · 2026
2. Abstract PS1-08-26: A phase 1/2, multi-part, open-label study of FWD1802, a novel oral selective estrogen receptor degrader (SERD), in patients with ER+/ HER2- locally advanced or metastatic breast cancer (BC)Clinical Cancer Research · 2026
3. Prevotella stecorea-Mediated Protection Against Infection in Rural African Children: Evidence for Microbiome Immunity2025
4. Role Attainment in Emerging Adulthood: Subjective Evaluation by Male Adolescents and Adults with Duchenne and Becker Muscular DystrophyJournal of Neuromuscular Diseases · 2022
5. RESUME-1: A Phase III Study of Tolperisone in the Treatment of Painful, Acute Muscle Spasms of the BackPain Management · 2021
6. A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathyEMBO Molecular Medicine · 2021
7. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprineJournal of Clinical Pharmacy and Therapeutics · 2020
8. Do Trabecular Metal Acetabular Components Reduce the Risk of Rerevision After Revision THA Performed for Periprosthetic Joint Infection? A Study Using the NJR Data SetClinical Orthopaedics and Related Research · 2018
9. Outcomes After Metal-on-metal Hip Revision Surgery Depend on the Reason for Failure: A Propensity Score-matched StudyClinical Orthopaedics and Related Research · 2018
10. Health Care Transition Experiences of Males with Childhood-onset Duchenne and Becker Muscular Dystrophy: Findings from the Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet) Health Care Transitions and Other Life Experiences SurveyPLoS Currents · 2018
11. A comparison of liprotamase, a non-porcine pancreatic enzyme replacement therapy, to porcine extracted pancrelipase in a noninferiority randomized clinical trial in patients with cystic fibrosisClinical Investigation · 2018
12. Descriptive Characteristics of Males with Duchenne Muscular Dystrophy in Those Covered by Government (Medicaid) and Non-government (Private) Health PlanstouchREVIEWS in Neurology · 2018
13. Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitusObesity · 2017
14. Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular DystrophyPLoS Currents · 2017
15. Effects of lorcaserin on pre‐existing valvulopathy: A pooled analysis of phase 3 trialsObesity · 2016
16. Barriers to drug adherence in the treatment of urea cycle disorders: Assessment of patient, caregiver and provider perspectivesMolecular Genetics and Metabolism Reports · 2016
17. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimodLupus · 2016
18. Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiserExpert Opinion on Biological Therapy · 2016
19. Characterization of pulmonary function in Duchenne Muscular DystrophyPediatric Pulmonology · 2015
20. Burden of Friedreich’s Ataxia to the Patients and Healthcare Systems in the United States and CanadaFrontiers in Pharmacology · 2013